The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Big pharma freshens up
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Wave waves goodbye to its first generation
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Takeda spreads it bets in Huntington’s
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
